This HTML5 document contains 42 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
wdthttp://www.wikidata.org/prop/direct/
schemahttp://schema.org/
rdfshttp://www.w3.org/2000/01/rdf-schema#
skoshttp://www.w3.org/2004/02/skos/core#
wikibasehttp://wikiba.se/ontology#
phttp://www.wikidata.org/prop/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
xsdhhttp://www.w3.org/2001/XMLSchema#
wdshttp://www.wikidata.org/entity/statement/
wdhttp://www.wikidata.org/entity/

Statements

Subject Item
wd:Q63831562
rdf:type
wikibase:Item
p:P248
wds:Q63831562-6F9577A2-1555-4F88-9BA0-471D3366B80C
wdt:P248
wd:Q51001464
schema:description
klinisch onderzoek ensayu clínicu клінічне випробування clinical trial
rdfs:label
Bevacizumab, Pemetrexed Disodium, and Cisplatin or Erlotinib Hydrochloride and Bevacizumab in Treating Patients With Stage IV Non-Small Cell Lung Cancer. A Multicenter Phase II Trial Including Biopsy at Progression (BIO-PRO Trial).
skos:prefLabel
Bevacizumab, Pemetrexed Disodium, and Cisplatin or Erlotinib Hydrochloride and Bevacizumab in Treating Patients With Stage IV Non-Small Cell Lung Cancer. A Multicenter Phase II Trial Including Biopsy at Progression (BIO-PRO Trial).
schema:name
Bevacizumab, Pemetrexed Disodium, and Cisplatin or Erlotinib Hydrochloride and Bevacizumab in Treating Patients With Stage IV Non-Small Cell Lung Cancer. A Multicenter Phase II Trial Including Biopsy at Progression (BIO-PRO Trial).
p:P1476
wds:Q63831562-4C1FCA8B-F068-436C-9D2F-376AC9806B16
wdt:P1476
Bevacizumab, Pemetrexed and Cisplatin, or Erlotinib and Bevacizumab for Advanced Non-Squamous NSCLC Stratified by EGFR Mutation Status. A Multicenter Phase II Trial Including Biopsy at Progression (BIO-PRO Trial).
p:P582
wds:Q63831562-A171A52D-532F-463B-AB99-03D310C08F7E
wdt:P582
2014-07-01T00:00:00Z
p:P31
wds:Q63831562-4C4B4880-8F1F-4FAC-AA53-502359525072
wdt:P31
wd:Q30612
p:P580
wds:Q63831562-5FDB8A23-113A-423F-AC4D-A86335228397
wdt:P580
2010-06-01T00:00:00Z
p:P17
wds:Q63831562-C8DFE6E0-E0CA-48E1-95C8-19A9C6EF5187
wdt:P17
wd:Q39
p:P6153
wds:Q63831562-9863C330-0D5E-4DFF-B132-01B1CAECFA75 wds:Q63831562-9C96AFCA-225A-4BA1-A800-431FE43622DA wds:Q63831562-5821DE1C-B768-4A38-A744-74CCE3C0F21D
wdt:P6153
wd:Q1728147 wd:Q1728146 wd:Q3145370
p:P4844
wds:Q63831562-F38A901D-9B9F-4ABD-BC69-B52560EF4712 wds:Q63831562-E9AB99E0-572C-437D-922D-87B129BB049D wds:Q63831562-21F1FB32-8270-45AF-9D3C-DA6F3E29F835
wdt:P4844
wd:Q415220 wd:Q412415 wd:Q413299
p:P2899
wds:Q63831562-945430E9-EE91-4133-837B-F7963771DC81
wdt:P2899
18
p:P1132
wds:Q63831562-31A91134-6295-40A0-BAC7-5A0B5F7AEF7E
wdt:P1132
149
p:P8363
wds:Q63831562-04AE9F3F-4B3C-4B7A-B3B2-67688A200C65
wdt:P8363
wd:Q78089383
p:P3098
wds:Q63831562-04819CBB-1838-45D4-B156-CA2AD285FF1A
wdt:P3098
NCT01116219
p:P6099
wds:Q63831562-EEF01AC2-A58E-4F64-8472-E6BA9ADF0C41
wdt:P6099
wd:Q42824440